Optimizing Safety Measures For rAAV Therapies

Gene therapy has progressed significantly over the last few decades, offering promising solutions for treating diseases that resist traditional medicines. One of the most commonly used vectors for in vivo gene therapy is the recombinant Adeno-Associated Virus (rAAV).

During rAAV production, impurities can originate from a number of process components and compromise patient safety if not properly removed during downstream purification. This article explores common process-related impurities found in rAAV vectors and the analytical testing methods used for these residuals.